NCT06081881

Brief Summary

to detect the incidence of CTEPH patients. Primary outcome To predict CETHP in symptomatic patients after pulmonary embolism episode. Secondary outcome: On Echocardiography revealed RV dysfunction which are peak TR Velocity , the RV/LV basal diameter ratio, flattening of the IVS, RV acceleration time and/or midsystolic notching, IVC diameter with decreased inspiratory collapse and RA area.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Jan 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress70%
Jan 2025Dec 2026

First Submitted

Initial submission to the registry

September 25, 2023

Completed
18 days until next milestone

First Posted

Study publicly available on registry

October 13, 2023

Completed
1.2 years until next milestone

Study Start

First participant enrolled

January 1, 2025

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

December 1, 2025

Status Verified

November 1, 2025

Enrollment Period

1.7 years

First QC Date

September 25, 2023

Last Update Submit

November 27, 2025

Conditions

Chronic Thromboembolic Pulmonary Hypertension

Keywords

CTEPH

Outcome Measures

Primary Outcomes (1)

  • Incidence of CTEHP in symptomatic patients after pulmonary embolism episode.

    Incidence of CTEHP in symptomatic patients after pulmonary embolism episode.

    3 years

Secondary Outcomes (1)

  • Measure of RV dysfunction by Echocardiography

    3 years

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients underwent pulmonary embolism episodes

You may qualify if:

  • Any patient diagnosed as acute pulmonary embolism ,aged between 18-80 years old which Pulmonary Embolism Severity Index (PESI) class III-V or sPESI ≥1,

You may not qualify if:

  • Secondary causes for pulmonary hypertension Severe kidney injury(eGFR\>30 mg/dl/1.7m2) Hepatic affection Contraindication to anti-coagulation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut University

Asyut, AssiutU, Egypt

RECRUITING

Study Officials

  • Ester A Faried, Resident

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ester A Faried, resident

CONTACT

01277194352esterashraf1810@gmail.com

Aly M Tohamy, Professor

CONTACT

01006258877Ali.Tohamy@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Physician Resident

Study Record Dates

First Submitted

September 25, 2023

First Posted

October 13, 2023

Study Start

January 1, 2025

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

December 1, 2025

Record last verified: 2025-11

Locations

EG(1)